Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous Nalbuphine for Prevention of Intrathecal Morphine-induced Nausea and Vomiting in Cesarean Section
NCT06837129Completed
- Sponsor
- Thammasat University
- Start
- Nov 2023
- Primary completion
- Feb 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, double-blind trial of nalbuphine in postoperative nausea and vomiting (PONV) (2 arms), sponsored by Thammasat University. Primary endpoint: Incidence of postoperative nausea vomiting at 24 hours. Started Nov 2023; status: completed.
02
Drugs
nalbuphine
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on NCT06837129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06837129.